Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective
AbstractThe incidence of numerous types of cancer has been increasing over recent years, representing the second-most frequent cause of death after cardiovascular diseases. Even though, the number of effective anticancer drugs is increasing as well, a large number of patients suffer from severe side effects (e.g., cardiomyopathies) caused by these drugs. This adversely affects the patients’ well-being and quality of life. On the molecular level, tumor cells that survive treatment modalities can become chemotherapy-resistant. In addition, adverse impacts on normal (healthy, stromal) cells occur concomitantly. Strategies that minimize these negative impacts on normal cells and which at the same time target tumor cells efficiently are needed. Recent studies suggest that redox-based combinational nanotherapies may represent one option in this direction. Here, we discuss recent advances in the application of nanoparticles, alone or in combination with other drugs, as a promising anticancer tool. Such novel strategies could well minimize harmful side effects and improve patients’ health prognoses. View Full-Text
Share & Cite This Article
Brenneisen, P.; Reichert, A.S. Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective. Antioxidants 2018, 7, 31.
Brenneisen P, Reichert AS. Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective. Antioxidants. 2018; 7(2):31.Chicago/Turabian Style
Brenneisen, Peter; Reichert, Andreas S. 2018. "Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective." Antioxidants 7, no. 2: 31.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.